Inventor · disambiguated record
Jason Grant Kettle
Also filed as: KETTLE JASON · KETTLE JASON G · KETTLE JASON GRANT
33 granted patents·23 pending applications·419 citations·filing 1998–2023
97Inventor score
Files withASTRAZENECA AB35DIZAL JIANGSU PHARMACEUTICAL CO LTD6BRADBURY ROBERT H5ASTRAZENECA UK LTD3ZENECA LTD3
Top patents by PatentIndex Score
56 records- 0195US10273227B2C5-anilinoquinazoline compounds and their use in treating cancerASTRAZENECA AB·Filed 2018·Granted Apr 30, 2019·11 cites·24 claims
- 0293US6479527B1Bicyclic pyrrole derivatives as MCP-1 inhibitorsASTRAZENECA UK LTD·Filed 2000·Granted Nov 12, 2002·74 cites·17 claims
- 0390US7718653B2Pyrimidine derivatives for inhibiting Eph receptorsASTRAZENECA AB·Filed 2008·Granted May 18, 2010·26 cites·14 claims
- 0490US7148230B2Quinazoline derivativesASTRAZENECA AB·Filed 2004·Granted Dec 12, 2006·42 cites·5 claims
- 0589US6833387B1Chemical compoundsASTRAZENECA AB·Filed 2000·Granted Dec 21, 2004·33 cites·8 claims
- 0688US9714236B2Compounds and methods for inhibiting JAKASTRAZENECA AB·Filed 2016·Granted Jul 25, 2017·6 cites·5 claims
- 0787US10961228B2JAK1 selective inhibitorsASTRAZENECA AB·Filed 2018·Granted Mar 30, 2021·3 cites·21 claims
- 0887US6441004B1Monocyte chemoattractant protein-1 inhibitor compoundsZENECA LTD·Filed 1998·Granted Aug 27, 2002·65 cites·15 claims
- 0986US11247983B2Compounds and methods for inhibiting JAKDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Feb 15, 2022·2 cites·19 claims
- 1086US10167276B2Compounds and methods for inhibiting JAKDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2017·Granted Jan 1, 2019·5 cites·5 claims
- 1185US12473272B2JAK1 selective inhibitorsASTRAZENECA AB·Filed 2023·Granted Nov 18, 2025·0 cites·9 claims
- 1285US6569888B1Anti-inflammatory indole derivativesASTRAZENECA AB·Filed 2000·Granted May 27, 2003·24 cites·9 claims
- 1385US6288103B1Indole derivatives as MCP-1 receptor antagonistsZENECA LTD·Filed 1998·Granted Sep 11, 2001·68 cites·17 claims
- 1484US10654835B2Compounds and methods for inhibiting JAKDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2018·Granted May 19, 2020·3 cites·22 claims
- 1583US11084827B2Triazolopyrimidine compounds and their use in treating cancerDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Aug 10, 2021·1 cites·18 claims
- 1681US6737435B1Indole derivatives and their use as MCP-1 antagonistASTRAZENECA AB·Filed 2000·Granted May 18, 2004·15 cites·9 claims
- 1780US6613760B1Indole derivatives and their use as MCP-1 receptor antagonistsASTRAZENECA AB·Filed 2000·Granted Sep 2, 2003·15 cites·8 claims
- 1879US12503473B2Triazolopyrimidine compounds and their use in treating cancerDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2023·Granted Dec 23, 2025·0 cites·6 claims
- 1977US6911465B1Anti-inflammatory indole derivativesASTRAZENECA AB·Filed 2000·Granted Jun 28, 2005·8 cites·8 claims
- 2073US11897869B2JAK1 selective inhibitorsASTRAZENECA AB·Filed 2021·Granted Feb 13, 2024·0 cites·24 claims
- 2171US6291507B1Chemical compoundsASTRAZENECA UK LTD·Filed 2000·Granted Sep 18, 2001·5 cites·17 claims
- 2270US11851432B2Triazolopyrimidine compounds and their use in treating cancerDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2021·Granted Dec 26, 2023·0 cites·20 claims
- 2370US8399667B24-anilino quinazoline derivatives as antiproliferative agentsBRADBURY ROBERT HUGH·Filed 2010·Granted Mar 19, 2013·1 cites·11 claims
- 2470US7625908B2Quinazoline derivativesASTRAZENECA AB·Filed 2004·Granted Dec 1, 2009·4 cites·21 claims
- 2570US6984657B1Indole derivatives as MCP-1 receptor antagonistsASTRAZENECA AB·Filed 2001·Granted Jan 10, 2006·4 cites·22 claims
- 2669US6953809B2Monocyte chemoattractant protein-1 inhibitor compoundsZENECA LTD·Filed 2002·Granted Oct 11, 2005·3 cites·7 claims
- 2768US10597405B2Chemical compoundsASTRAZENECA AB·Filed 2018·Granted Mar 24, 2020·1 cites·18 claims
- 2865US2008269487A14-anilino quinazoline derivatives as antiproliferative agentsASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 2964US10829479B2C5-anilinoquinazoline compounds and their use in treating cancerASTRAZENECA AB·Filed 2019·Granted Nov 10, 2020·0 cites·22 claims
- 3060US2022127281A1Heteroaryl compounds that inhibit g12c mutant ras proteinsASTRAZENECA AB·Filed 2021·Application pending·0 cites
- 3158US2013005727A1Quinazoline derivativesASTRAZENECA AB·Filed 2012·Application pending·0 cites
- 3257US11407765B2Tetracyclic heteroaryl compoundsASTRAZENECA AB·Filed 2019·Granted Aug 9, 2022·0 cites·19 claims
- 3357US2024374606A1Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancerASTRAZENECA AB·Filed 2022·Application pending·0 cites
- 3457US2007088044A1Quinazoline derivatives as antitumor agentsASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 3556US12410187B2Fused tricyclic compounds useful as anticancer agentsASTRAZENECA AB·Filed 2020·Granted Sep 9, 2025·0 cites·5 claims
- 3655US2005215574A14-anilino quinazoline derivatives as antiproliferative agentsBRADBURY ROBERT H·Filed 2003·Application pending·0 cites
- 3752US2007082921A1Quinazoline derivatives as antitumor agentsASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 3850US11053223B2Phenoxyquinazoline compounds and their use in treating cancerASTRAZENECA AB·Filed 2018·Granted Jul 6, 2021·0 cites·10 claims
- 3950US2023374007A1Compounds and their use in treating cancerASTRAZENECA AB·Filed 2021·Application pending·0 cites
- 4048US2005043336A1Quinazoline derivatives as antitumor agentsFiled 2002·Application pending·0 cites
- 4148US2007015743A1Quinazoline derivatives as antitumor agentsBRADBURY ROBERT H·Filed 2004·Application pending·0 cites
- 4248US2007032508A1Quinazoline derivatives as tyrosine kinase inhibitorsBRADBURY ROBERT H·Filed 2004·Application pending·0 cites
- 4347US2005054662A1Quinazoline derivatives as antitumor agentsFiled 2002·Application pending·0 cites
- 4447US2005026975A1Anti-inflammatory indole derivativesASTRAZENECA AB·Filed 2004·Application pending·0 cites
- 4547US2007149546A14-Anilino-quinazoline derivatives as antiproliferative agentsBRADBURY ROBERT H·Filed 2004·Application pending·0 cites
- 4645US10519152B2Compounds and their use in treating cancerASTRAZENECA AB·Filed 2018·Granted Dec 31, 2019·0 cites·12 claims
- 4745US2020109153A1Heteroaryl compounds that inhibit g12c mutant ras proteinsASTRAZENECA AB·Filed 2018·Application pending·0 cites
- 4845US2007099943A1Quinazoline derivativesASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 4945US2007232607A1Quinazoline Derivatives as Erbb Receptor Tyrosine kinasesBRADBURY ROBERT H·Filed 2005·Application pending·0 cites
- 5045US2009203663A1Chemical compoundsASTRAZENECA AB·Filed 2007·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jason Grant Kettle files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →